Developing a Kinder & Gentler More Efficacious CEACAM5 ADC
- Contextualising lessons learned from the current ADC clinical development landscape and advocating for an enhanced focus on addressing tolerability to improve ADC performance and success for patients
- Pursuing less toxic ADC development to evolve dosing to be equivalent to naked antibody therapies and expand therapeutic index
- Highlighting differentiation strategy for kinder and gentler ADC development, headlined with preclinical profile of KIVU-305 against solid tumours